Ruijin Hospital: Lymphoma, T-Cell, Peripheral trials

The registry lists 24 Lymphoma, T-Cell, Peripheral studies with Ruijin Hospital as lead sponsor. 16 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 14Phase 3 3Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingNCT07706959Phase 1/2
• A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.Not yet recruitingNCT07657572
• Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingNCT07279584Phase 2
• Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07209163Phase 1/2
• Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingNCT07081607Phase 2
• A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell LymphomaNot yet recruitingNCT06963632
• Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingNCT06701344Phase 2
• The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaNot yet recruitingNCT06255795Phase 3
• Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)RecruitingNCT05934864
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• Genotype-guided Treatment in Newly Diagnosed PTCLRecruitingNCT05675813Phase 1/2
• PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell LymphomaRecruitingNCT05662540Not applicable
• A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
• Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell LymphomaRecruitingNCT05367856Phase 2
• Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical StudyRecruitingNCT04880746Phase 3
• Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
• Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
• Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
• Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
• Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
• Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaStatus unknownNCT02753543Phase 2
• MESA Versus ESA in the Treatment of Early Stage NK/T-cell LymphomaStatus unknownNCT02631239Phase 3
• CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 4